What chemotherapy regimens are used for Endometrial Cancer

Chemotherapy Regimens for Endometrial Cancer

I'll walk you through the main chemotherapy approaches used for endometrial cancer, organized by treatment setting.

FIRST-LINE CHEMOTHERAPY FOR ADVANCED/RECURRENT DISEASE

According to the NCCN Guidelines for Endometrial Carcinoma, the preferred first-line chemotherapy regimens have evolved significantly with the addition of immunotherapy combinations:

Preferred Combination Regimens (Category 1)

1. Pembrolizumab + Carboplatin + Paclitaxel

• This immunotherapy-chemotherapy combination is now a preferred option based on the NRG-GY018 trial
• Works particularly well for patients with dMMR (deficient mismatch repair) tumors, showing a 74% progression-free survival (PFS) at 2 years
• For pMMR (proficient mismatch repair) tumors, median PFS was 13.1 months versus 8.7 months with chemotherapy alone

2. Dostarlimab + Carboplatin + Paclitaxel

• Another preferred first-line option based on the RUBY trial
• At 24 months: 36.1% PFS versus 18.1% with chemotherapy alone
• Shows even stronger benefits in dMMR/MSI-H tumors (61.4% vs 15.7% PFS)
• Demonstrated overall survival benefit in recent analysis

3. Durvalumab + Carboplatin + Paclitaxel

• Recommended as a Category 1 preferred regimen specifically for dMMR tumors
• Based on the DUO-E trial and FDA approval

Standard Chemotherapy Doublet (Without Immunotherapy)

Carboplatin + Paclitaxel

• Response rate: 40-62%
• Median overall survival: 13-29 months
• This remains a foundational regimen and is preferred over older three-drug combinations because it has better tolerability
• The GOG-209 trial showed similar outcomes to older regimens (cisplatin/doxorubicin/paclitaxel) but with significantly less toxicity

---

CHEMOTHERAPY FOR SPECIFIC HISTOLOGIES

For HER2-Positive Uterine Serous Carcinoma:

• Carboplatin + Paclitaxel + Trastuzumab is recommended as a preferred first-line option
• Trastuzumab targets the HER2 protein on cancer cells

---

ALTERNATIVE COMBINATION REGIMENS

According to NCCN Guidelines, these are also used as first-line options:

• Carboplatin + Docetaxel (when paclitaxel is contraindicated)
• Carboplatin + Paclitaxel + Bevacizumab (anti-angiogenic therapy)
  • Median PFS: 20 months
  • Median overall survival: 56 months in one analysis
  • Overall response rate: 82.8%

---

SECOND-LINE AND SUBSEQUENT THERAPY OPTIONS

If first-line chemotherapy doesn't work or the cancer progresses, doctors may consider:

Multiagent Regimens:

• Cisplatin + Doxorubicin
• Cisplatin + Doxorubicin + Paclitaxel (older regimen, less commonly used due to higher toxicity)
• Ifosfamide + Paclitaxel (for carcinosarcoma)

Single-Agent Options:

• Paclitaxel (most active single agent; 4-27% response rate)
• Liposomal doxorubicin (9.5% response rate, less toxic than standard doxorubicin)
• Carboplatin
• Topotecan
• Gemcitabine
• Bevacizumab
• Lenvatinib
• Cabozantinib

---

IMPORTANT CONTEXT: WHY THESE COMBINATIONS?

The shift toward immunotherapy-chemotherapy combinations reflects new understanding about endometrial cancer biology. Immunotherapy drugs (like pembrolizumab and dostarlimab) work by "releasing the brakes" on your immune system so it can recognize and attack cancer cells. When combined with chemotherapy, which damages cancer cells and makes them more visible to the immune system, the results are stronger.

Key factors your oncologist considers:

• Your tumor's molecular profile (dMMR vs pMMR status)
• Cancer histology (endometrioid vs serous vs clear cell)
• Stage of disease
• Prior treatments you've received
• Your overall health and ability to tolerate side effects
• Whether you've had chemotherapy before

---

QUESTIONS TO ASK YOUR ONCOLOGIST

1. What is my tumor's molecular profile (dMMR/MSI-H status)? This significantly impacts which regimen is recommended.
2. Which chemotherapy regimen do you recommend for my specific situation, and why?
3. Will I receive immunotherapy combined with chemotherapy, or chemotherapy alone?
4. What are the expected response rates and side effects for the regimen you're recommending?
5. How will we monitor whether the treatment is working?
6. What are my options if this regimen doesn't work or I can't tolerate it?

---

SOURCES

According to the NCCN Guidelines for Endometrial Carcinoma (Version 1.2026), these regimens represent the current standard of care based on multiple randomized clinical trials including NRG-GY018, RUBY, and DUO-E trials. The American Society of Clinical Oncology (ASCO) endorses these NCCN recommendations for postoperative radiation therapy and systemic therapy decisions.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.